DNLI: Total Utang marang Modal Denali Therapeutics Inc.

Logo perusahaan publik Denali Therapeutics Inc. (DNLI)

Denali Therapeutics (DNLI) leverages AI and robotics to automate the search for treatments for neuronal degeneration, thereby accelerating preclinical stages. The business model relies on the high margins of patented drugs coupled with global distribution. The debt-to-equity ratio trend on GURU.Markets stands at 0.05. The company's operations are further supported by adherence to environmental standards for chemical disposal and office energy efficiency.

DNLI - Total Utang marang Modal Denali Therapeutics Inc. ing rentang 04.07.2022 - 31.10.2026

Rincian metrik lan analitis perusahaan Denali Corp (DNLI)

- rega lan prakiraan konsensus rega:
Bagan rega Denali Therapeutics Inc.|DNLI - Prakiraan gabungan firma investasi
- informasi kapitalisasi pasar:
Kapitalisasi pasar Denali Therapeutics|DNLI - Total Nilai Perusahaan
- indikator kapitalisasi buku:
Nilai Akuntansi saben Saham Denali Therapeutics|DNLI - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku denalitherapeutics.com|DNLI - Nilai Agregat Aset
- indikator beban kredit lan likuiditas emiten:
Utang marang Ekuitas Denali Therapeutics|DNLI - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang modal Denali Therapeutics|DNLI - Utang agregat perusahaan|Utang-utang marang kapitalisasi buku Denali Therapeutics|DNLI - Utang jangka dawa|Utang jangka cendhak perusahaan Denali Therapeutics|Rasio cepet denalitherapeutics.com
- statistik bathi lan rasio pasar:
DNLI - Bathi resik
Analisis umum perusahaan:Denali Therapeutics Inc., DNLI
Barang utama Denali Corp

The specific operational model of Denali Therapeutics (DNLI), which delegates the production of neuro-drugs to contractors, minimizes capital expenditures, a factor reflected in its financing structure. The current value of 0.05 is calculated as the ratio of total liabilities to equity, measuring the company's degree of reliance on borrowed funds. An analysis of the financial leverage ratio (total debt-to-equity) determines the resilience of the business model in the face of potential debt risks.

Pesaing Denali Therapeutics

Utang marang Ekuitas Biogen|Rasio Utang marang Ekuitas NBIX (Neurocrine)|Total Utang marang Modal RGC|AXSM - Utang marang Modal|ACADIA Pharmaceuticals - Rasio Total Utang marang Ekuitas|Total Utang marang Modal xenon-pharma.com XENE|VKTX - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi SUPN (Supernus Pharmaceuticals, Inc.)|Catalyst Pharmaceuticals Inc (CPRX) - Utang marang Ekuitas|Utang marang Modal Harmony Corp (HRMY)|BHVN (Biohaven Ltd.) - Total Utang marang Modal|Rasio Utang marang Ekuitas AMLX (amylyx.com)|Total Utang marang Modal TRVI|PRAX - Utang marang Modal|Utang marang Ekuitas Anavex Corp AVXL|CBLL: Rasio Utang marang Ekuitas|Prothena Corporation plc - Total Utang marang Modal|ALEC - Total Utang marang Modal|Annexon (ANNX) - Utang marang Ekuitas|OMER (Omeros) - Utang marang Ekuitas|NGNE (Neurogene Corp) - Total Utang marang Modal|AC Immune Inc (ACIU) - Koefisien Total Utang marang Modal|Rasio Total Utang marang Ekuitas VYGR (Voyager Therapeutics)|NMRA (neumoratx.com) - Rasio Kabeh Utang marang Dana Pribadi|Scilex - Rasio Total Utang marang Ekuitas|Utang Agregat marang Modal TVGN (Tevogen Bio Holdings Inc.)|Alpha Cognition Corp - Total Utang marang Modal|Rasio Kabeh Utang marang Dana Pribadi CGTX (Cognition Therapeutics Inc.)|IKT: Total Utang marang Modal|Utang marang Modal cassavasciences.com (SAVA)|Utang marang Ekuitas Assertio Holdings|COYA: Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal VTGN|Total Utang marang Modal ovidrx.com (OVID)|Utang marang Ekuitas Acumen Pharmaceuticals ABOS|CRVO (cervomed.com) - Utang Agregat marang Ekuitas|Alterity Therapeutics Ltd - Total Utang marang Modal|Utang marang Modal Clene Inc.|PEPG (pepgen.com) - Rasio Total Utang marang Ekuitas|Jupiter Neurosciences, Inc. (JUNS) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas RLMD|ANVS (annovisbio.com) - Utang Agregat marang Modal|Total Utang marang Modal GRCE|Koefisien Total Utang marang Modal Firefly Neuroscience, Inc.|Total Utang marang Modal KLTO (Klotho Neurosciences)|NRSN - Rasio Total Utang marang Ekuitas|RVPH - Utang marang Ekuitas|Koefisien Total Utang marang Modal MetaVia Inc MTVA|NRXS: Total Utang marang Modal|Rasio Utang marang Ekuitas HSDT|Utang marang Ekuitas Passage Bio Inc.|Rasio Utang marang Ekuitas NEUP (Neuphoria)|Utang marang Ekuitas Minerva Neurosciences (NERV)|Utang marang Ekuitas ATHA (athira.com)|Total Utang marang Modal ADXN (Addex Therapeutics Ltd)|Koefisien Total Utang marang Modal Alzamend Neuro Inc. (ALZN)|CYCN - Utang marang Ekuitas|PTIX (Protagenic Therapeutics) - Rasio Utang marang Ekuitas|KTTA: Total Utang marang Modal|Utang marang Modal Cortigent (CRGT)|Rasio Total Utang marang Ekuitas ATXI|Total Utang marang Modal Brainstorm Cell Therapeutics Inc.|Utang marang Ekuitas Cara Therapeutics, Inc (CARA)|CHRO (Chromocell) - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Eliem Therapeutics Inc. ELYM|Intra-Cellular Therapies Inc. (ITCI) - Utang marang Modal|Longboard Pharmaceuticals, Inc. - Total Utang marang Modal|MRNS (Marinus Pharmaceuticals Inc) - Rasio Utang marang Ekuitas|NKGN: Total Utang marang Modal|Utang marang Modal NeuroBo Pharma (NRBO)|Utang marang Ekuitas Sage Therapeutics, Inc.|Rasio Utang marang Ekuitas SNPX (synaptogen.com)|Total Utang marang Modal TRVN|Total Utang marang Modal vigilneuro.com (VIGL)|Utang marang Ekuitas Anew Medical WENA|Cerevel Corp - Utang marang Ekuitas